AR126001A1 - Anticuerpos y composiciones anti-nkg2a - Google Patents
Anticuerpos y composiciones anti-nkg2aInfo
- Publication number
- AR126001A1 AR126001A1 ARP220101426A ARP220101426A AR126001A1 AR 126001 A1 AR126001 A1 AR 126001A1 AR P220101426 A ARP220101426 A AR P220101426A AR P220101426 A ARP220101426 A AR P220101426A AR 126001 A1 AR126001 A1 AR 126001A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- nos
- amino acid
- acid sequences
- nkg2a
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195470P | 2021-06-01 | 2021-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126001A1 true AR126001A1 (es) | 2023-08-30 |
Family
ID=82117230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101426A AR126001A1 (es) | 2021-06-01 | 2022-05-31 | Anticuerpos y composiciones anti-nkg2a |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12012450B2 (https=) |
| EP (1) | EP4347651A1 (https=) |
| JP (1) | JP2024520577A (https=) |
| KR (1) | KR20240016991A (https=) |
| CN (1) | CN117460748A (https=) |
| AR (1) | AR126001A1 (https=) |
| AU (1) | AU2022286617A1 (https=) |
| BR (1) | BR112023024772A2 (https=) |
| CA (1) | CA3222040A1 (https=) |
| CL (1) | CL2023003562A1 (https=) |
| CO (1) | CO2023015982A2 (https=) |
| IL (1) | IL308695A (https=) |
| MX (1) | MX2023014320A (https=) |
| PE (1) | PE20240372A1 (https=) |
| PH (1) | PH12023553123A1 (https=) |
| TW (1) | TW202313683A (https=) |
| WO (1) | WO2022253805A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024140820A1 (zh) * | 2022-12-28 | 2024-07-04 | 浙江博锐生物制药有限公司 | 抗nkg2a抗体及其用途 |
| WO2024260280A1 (en) * | 2023-06-21 | 2024-12-26 | Elpiscience (Suzhou) Biopharma, Ltd. | Antibodies or antigen-binding fragments binding to nkg2a and uses thereof |
| CN121941711A (zh) * | 2024-02-08 | 2026-04-28 | 翰思艾泰生物医药科技(武汉)股份有限公司 | Nkg2a/cd94靶向抗体及其用途 |
| CN121108342B (zh) * | 2025-09-08 | 2026-03-03 | 北京明璨生物科技有限公司 | 包含抗体和nk细胞的组合物在治疗癌症中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| KR20100110864A (ko) * | 2008-01-24 | 2010-10-13 | 노보 노르디스크 에이/에스 | 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체 |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| US10329348B2 (en) * | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| PH12018502112B1 (en) | 2016-04-12 | 2024-03-27 | Servier Lab | Anti-tim-3 antibodies and compositions |
| US12534526B2 (en) | 2018-11-07 | 2026-01-27 | Shanghai Hyamab Biotech Co., Ltd. | NKG2A antibody, preparation method therefor and application thereof |
| CN113316590B (zh) * | 2018-11-16 | 2025-02-28 | 百时美施贵宝公司 | 抗nkg2a抗体及其用途 |
-
2022
- 2022-05-31 WO PCT/EP2022/064703 patent/WO2022253805A1/en not_active Ceased
- 2022-05-31 EP EP22732067.8A patent/EP4347651A1/en active Pending
- 2022-05-31 MX MX2023014320A patent/MX2023014320A/es unknown
- 2022-05-31 AR ARP220101426A patent/AR126001A1/es unknown
- 2022-05-31 PH PH1/2023/553123A patent/PH12023553123A1/en unknown
- 2022-05-31 TW TW111120182A patent/TW202313683A/zh unknown
- 2022-05-31 IL IL308695A patent/IL308695A/en unknown
- 2022-05-31 BR BR112023024772A patent/BR112023024772A2/pt unknown
- 2022-05-31 JP JP2023573662A patent/JP2024520577A/ja active Pending
- 2022-05-31 AU AU2022286617A patent/AU2022286617A1/en active Pending
- 2022-05-31 CA CA3222040A patent/CA3222040A1/en active Pending
- 2022-05-31 KR KR1020237043690A patent/KR20240016991A/ko active Pending
- 2022-05-31 PE PE2023003150A patent/PE20240372A1/es unknown
- 2022-05-31 US US17/828,740 patent/US12012450B2/en active Active
- 2022-05-31 CN CN202280039227.XA patent/CN117460748A/zh active Pending
-
2023
- 2023-11-23 CO CONC2023/0015982A patent/CO2023015982A2/es unknown
- 2023-11-29 CL CL2023003562A patent/CL2023003562A1/es unknown
-
2024
- 2024-05-13 US US18/661,970 patent/US20240294638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220389100A1 (en) | 2022-12-08 |
| TW202313683A (zh) | 2023-04-01 |
| US12012450B2 (en) | 2024-06-18 |
| CN117460748A (zh) | 2024-01-26 |
| AU2022286617A1 (en) | 2023-12-21 |
| CO2023015982A2 (es) | 2024-01-15 |
| PE20240372A1 (es) | 2024-03-05 |
| EP4347651A1 (en) | 2024-04-10 |
| CA3222040A1 (en) | 2022-12-08 |
| WO2022253805A1 (en) | 2022-12-08 |
| JP2024520577A (ja) | 2024-05-24 |
| KR20240016991A (ko) | 2024-02-06 |
| BR112023024772A2 (pt) | 2024-02-15 |
| MX2023014320A (es) | 2023-12-13 |
| PH12023553123A1 (en) | 2024-03-04 |
| IL308695A (en) | 2024-01-01 |
| CL2023003562A1 (es) | 2024-07-12 |
| US20240294638A1 (en) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126001A1 (es) | Anticuerpos y composiciones anti-nkg2a | |
| PE20231851A1 (es) | Proteinas que se unen a nkg2d, cd16 y clec12a | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| MX2024002152A (es) | Anticuerpos anti-ccr8 y usos de estos. | |
| PE20240363A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PH12021550793A1 (en) | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | |
| PE20090046A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| CO5160384A1 (es) | Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20110797A1 (es) | Anticuerpos anti mn | |
| PE20050712A1 (es) | Anticuerpos rg1 | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| PE20221263A1 (es) | Agentes de union a ilt3 y metodos de uso de los mismos | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| SA523451800B1 (ar) | Sirp أجسام مضادة لـ ألفا | |
| MX2024001067A (es) | Composicion farmaceutica y uso. | |
| MX2024015285A (es) | Anticuerpos anti-egfr/met y usos de los mismos | |
| PE20230306A1 (es) | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| CL2018003072A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| PE20230075A1 (es) | Anticuerpos anti-flt3 y composiciones | |
| PE20230374A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos |